Pfizer 10-Q Details $4.3B Impairments, New $2.5B Savings Push Behind Raised Guidance
PFE sits 30% above its 52-week low of $23.62.
Summary
Pfizer's Q3 10-Q backs up its raised guidance with full financials: nine-month net income down 40% to $5.68 billion on $4.3 billion of impairments, offset by $8.8 billion of operating cash flow and a new $2.5 billion cost-savings push.
Key Events · Earnings and Guidance · PFE
-
Q3 Revenue Flat, Non-COVID Up 7%
Third-quarter 2026 revenues were $16,583 million versus $16,654 million a year earlier; excluding Comirnaty and Paxlovid, revenue grew 7% operationally.
-
$4.3B Impairments Hit Nine-Month Earnings
Nine-month net income attributable to Pfizer fell to $5,681 million from $9,419 million, driven by $4,325 million of impairments — $3.8 billion on sigvotatug vedotin IPR&D and $525 million on Oxbryta developed technology rights.
-
New $2.5B Cost-Savings Round Announced
Pfizer added $1.0 billion of net savings to its Realigning Our Cost Base Program and launched a next manufacturing phase targeting ~$1.5 billion of savings, with one-time costs of ~$4.0 billion through 2029 (about 60% non-cash).
-
Operating Cash Flow Rises to $8.8B
Nine-month operating cash flow was $8,825 million versus $6,356 million a year earlier, helped by the $1.875 billion ViiV sale proceeds and lower upfront licensing payments ($650 million to Innovent versus $1.35 billion to 3SBio).
Analysis · PFE · Life Sciences
This filing is the full financial backup to Pfizer's same-day Q3 earnings release, and it carries the parts the press release only summarized. Nine-month net income fell 40% to $5.68 billion, dragged by $4.325 billion of intangible write-downs — $3.8 billion on the failed sigvotatug vedotin lung-cancer program and $525 million on Oxbryta after the FDA confirmed no path back to market. Against that, Pfizer announced a fresh round of cost cuts in Q3: $1.0 billion of additional net savings in the Realigning Our Cost Base Program and a next phase of manufacturing optimization worth about $1.5 billion, at a one-time cost of roughly $4.0 billion (about 60% non-cash). Cash generation is the offset — operating cash flow rose to $8.8 billion from $6.4 billion — and the balance sheet still carries $60 billion of long-term debt against $14.3 billion of cash and short-term investments. The write-downs explain why reported EPS ($0.56) sits well below adjusted EPS ($0.87), which is the number behind the raised $2.95-$3.05 guidance.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PFE was trading at $30.66 on NYSE in the Life Sciences sector, with a market capitalization of approximately $174.8B. The 52-week trading range was $23.62 to $31.04. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.